Long-term outcome of high-grade encapsulated papillary carcinoma of the breast: implications for staging and management

Background: Encapsulated papillary carcinoma (EPC) of the breast is an uncommon tumour with controversial biological behaviour and staging. Emerging evidence suggests that EPC with adverse pathological features (EPC-A) may exhibit invasive potential. The absence of uniform staging criteria contributes to management variability. This study evaluates the clinicopathological characteristics and clinical course of high-grade EPC (HG-EPC), including EPC-A. Materials and methods: This retrospective multicentre study (2000-2025) included 25 HG-EPC cases, irrespectively of ER/PR and HER2 status. Tumours with frank stromal invasion beyond microinvasive foci were excluded. Histopathological re-evaluation was performed in accordance with 2019 WHO classification criteria. Results: Of 38 cases reviewed, 25 fulfilled the inclusion criteria as EPC (mean age 57.2 years, mean tumour size 2.9 cm). Six cases (24%) demonstrated conventional-type microinvasive components. A subset of 16 cases fulfilled criteria for EPC-A, defined by high-grade morphology in combination with ER/PR-negative (or ER <30% positive) and/or HER2-positive status. Staging and management were variable. Initial pathological stage varied: pTis (n = 13) to pT1 (n = 4) or pT2 (n = 7), and pT3 (n = 1). Adjuvant chemotherapy and radiotherapy were administered in 7 and 12 patients respectively. During follow-up, four local recurrences (three invasive and one in situ) were observed. One of the locally recurrent patients subsequently developed distant metastasis, and one breast cancer-related death occurred 200 months after diagnosis. Recurrence or death occurred in 20% (5/25) of patients despite therapy. Microinvasion was seen only in the EPC-A tumours. Conclusion: HG-EPC and EPC-A overlap morphologically and diagnostically with frankly invasive carcinomas and demonstrate a non-negligible risk of recurrence. Clinical outcomes and more frequent microinvasion in EPC-A support the view that EPC-A is more appropriately regarded as an indolent form of invasive carcinoma rather than a purely in situ lesion and demonstrate a non-negligible risk of recurrence and highlight the need for standardized staging criteria.

Authors

Publication Details

Published
2026-08-03
DOI
https://doi.org/10.5167/uzh-435371
Primary Topic
Breast Lesions and Carcinomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term outcome of high-grade encapsulated papillary carcinoma of the breast: implications for staging and management

Umberto Macciò, Bärbel Papassotiropoulos, Zsuzsanna Varga, Emad A. Rakha et al.
Breast Lesions and Carcinomas
article

Long-term outcome of high-grade encapsulated papillary carcinoma of the breast: implications for staging and management

Umberto Macciò, Bärbel Papassotiropoulos, Zsuzsanna Varga, Emad A. Rakha, Isabell Witzel, Heike Frauchiger-Heuer, Lidija Stevanovic, Hisham Fansa, Milena Stevanovic, Ian O Ellis
article en

Abstract

Background: Encapsulated papillary carcinoma (EPC) of the breast is an uncommon tumour with controversial biological behaviour and staging. Emerging evidence suggests that EPC with adverse pathological features (EPC-A) may exhibit invasive potential. The absence of uniform staging criteria contributes to management variability. This study evaluates the clinicopathological characteristics and clinical course of high-grade EPC (HG-EPC), including EPC-A. Materials and methods: This retrospective multicentre study (2000-2025) included 25 HG-EPC cases, irrespectively of ER/PR and HER2 status. Tumours with frank stromal invasion beyond microinvasive foci were excluded. Histopathological re-evaluation was performed in accordance with 2019 WHO classification criteria. Results: Of 38 cases reviewed, 25 fulfilled the inclusion criteria as EPC (mean age 57.2 years, mean tumour size 2.9 cm). Six cases (24%) demonstrated conventional-type microinvasive components. A subset of 16 cases fulfilled criteria for EPC-A, defined by high-grade morphology in combination with ER/PR-negative (or ER <30% positive) and/or HER2-positive status. Staging and management were variable. Initial pathological stage varied: pTis (n = 13) to pT1 (n = 4) or pT2 (n = 7), and pT3 (n = 1). Adjuvant chemotherapy and radiotherapy were administered in 7 and 12 patients respectively. During follow-up, four local recurrences (three invasive and one in situ) were observed. One of the locally recurrent patients subsequently developed distant metastasis, and one breast cancer-related death occurred 200 months after diagnosis. Recurrence or death occurred in 20% (5/25) of patients despite therapy. Microinvasion was seen only in the EPC-A tumours. Conclusion: HG-EPC and EPC-A overlap morphologically and diagnostically with frankly invasive carcinomas and demonstrate a non-negligible risk of recurrence. Clinical outcomes and more frequent microinvasion in EPC-A support the view that EPC-A is more appropriately regarded as an indolent form of invasive carcinoma rather than a purely in situ lesion and demonstrate a non-negligible risk of recurrence and highlight the need for standardized staging criteria.

Openalex Percentile: Top 9%
Breast Lesions and Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.